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Background: Although preeclampsia (PE), as an endothelial disorder can lead to renal 
dysfunction during pregnancy, results of studies focusing on the potential long term potential 
effects of preeclampsia on renal function are insufficient and those available are controversial. 
This study investigated the incidence rate and risk of chronic kidney disease (CKD) among women 
with prior history of PE compared with healthy-controls in a long-term population-based study. 
Methods: This was a prospective population-based cohort study. Subjects were 1851 eligible 
women, aged 20–50 years, with at least one pregnancy (177 women with prior-PE and 1674 non-
PE controls) selected from among the Tehran-Lipid and Glucose-Study-participants. A pooled-
logistic-regression-model and Cox’s-proportional-hazards-models were utilized to estimate the 
risk of CKD in women of both PE and without PE groups, after further adjustment for confounders. 
Results: Median and interquartile ranges for follow-up durations of the PE and non-PE groups 
were 7.78 (5.19-10.40) and 7.32 (4.73-11.00) years, respectively. Total cumulative incidence rates 
of CKD at the median follow-up time of each group was 35/100000 (95% CI: 25/100000, 
50/100000) and 36/100000 (95% CI: 32/100000, 39/100000) in PE and non-PE women 
respectively. (P-value= 0.90). Based on pooled-logistic-regression-analysis, OR of CKD 
progression (adjusted for age, BMI, SBP and DBP) for the PE group did not differ, compared to 
their non-PE counterparts. (OR: 1.04; P-value= 0.80; 95% CI: 0.77, 1.40). Compared to non-PE 
women, women with prior PE did not have higher hazard ratios of developing CKD in the 
unadjusted model (unadjusted HR 1.1; 95% CI, 0.83–1.69; P = 0.35), results which remained 
unchanged after adjustment for age, BMI, baseline SBP and DBP.  
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Conclusion: Preeclampsia was not found to be a risk factor for CKD. More studies using a 
prospective cohort design with long term follow-ups are needed to investigate the relationship 
between preeclamsia and CKD. 
Keywords: preeclampsia, chronic kidney disease, prospective population- based study, Tehran-
Lipid and Glucose-Study (TLGS). 
Introduction 
Preeclampsia (PE) is a multisystem disorder affecting 3%–10% of all pregnant women with 
simultaneous increased rates of obesity, advanced maternal age and nulliparity [1, 2]. This disorder 
constitutes as a major cause of maternal morbidity and mortality worldwide.  
The exact underlying etiology and pathogenesis of PE remains unknown, although it has been 
shown that genetic, immunological and environmental factors are associated with the endothelial 
dysfunction of PE [3]. Moreover, the imbalance of proangiogenic and anti-angiogenic proteins and 
disturbances in the renin–angiotensin aldosterone system, common mechanisms in chronic kidney 
disease, may play an important role in PE [4, 5]. Endothelial dysfunction in PE can also affect 
kidney function; it is well documented that PE is strongly associated with acute kidney 
dysfunction, viz. glomerular endotheliosis [6]. Kidney dysfunction, reflected by either decreased 
glomerular filtration rate (GFR) or albuminuria that usually recovers within six weeks of birth [7], 
unless there is glomerular scarring [8]. Nonetheless, some women may experience persistently 
decreased kidney function long after their complicated pregnancy with PE [9].  
Relatively little is known about its long term effects on the kidney function later in life and data 
available reveal conflicting results. While some studies report kidney dysfunction can be resolved 
in most women with a history of PE [10-13], it has been shown that some women with PE may 
experience decreased glomerular filtration rate (GFR) and/or persistent proteinuria and/or 
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increased risk of CKD after PE [9, 14-18], discrepancies which may be partly explained by 
differences in ethnicities, study design, definition of kidney function and limited follow-up 
durations after pregnancy.  
Considering the data available on the history of PE of the Tehran-Lipid and Glucose-Study (TLGS) 
participants enabled us to compare the incidence of CKD events among women with a prior history 
of PE compared with healthy controls in a long-term population-based study. 
Methods 
The Medical Ethics Committee of the Research Institute for Endocrine Sciences approved the 
research protocol. Written informed consent was obtained from all participants before the initiation 
of the study. (Ethic code: IR.SBMU.ENDOCRINE.REC.1398074) 
Study population  
This was a prospective cohort study with a 15-year follow-up conducted among 1851 women aged 
20-50 years diagnosed with and without PE after the index pregnancy. The study participants were 
recruited from the Tehran Lipid and Glucose Study (TLGS). An ongoing study, initiated in 1998 
to investigate the prevalence and risk factors of non-communicable diseases, in particular, 
cardiovascular risk factors. Briefly, in the TLGS, a total of 15,005 individuals, aged ≥ 3 years, 
were followed within 3-years intervals to collect data on demographic, anthropometric, 
reproductive and metabolic characteristics, general physical examinations, and laboratory 
measurements. Details of the procedures of TLGS have been published previously [19]. All 
participants were visited at the outpatient clinic of TLGS between February 1999 and August 2001. 
At initiation of our study, TLGS completed five phases with 3-year intervals (phase 1: 1999-2001, 
phase 2: 2002-2005, phase 3: 2005- 2008, phase 4: 2008- 2011 and phase 5: 2011- 2014). 
Therefore, current data were available for five phases including baseline and four follow-ups.  
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At the beginning of this study, all women, aged 20-50 years with at least one pregnancy were 
assessed (n= 3901), of whom  499 women had a history of PE during their pregnancies and 3402 
did not. All women who were present at the baseline of the study and had at least one follow-up 
visit were included. Excluded were women with CKD (n= 203), hypertension (HTN) (n= 1265), 
CKD plus HTN (n= 224), and those without at least one follow up visit (n= 358). Finally, a total 
of 1851 women were recruited to participate in this study (Figure 1).  
Measurements   
All clinical, anthropometric, and biochemical parameters were measured by trained interviewers 
at baseline and follow-up visits; detailed descriptions of the measurements in TLGS have been 
published elsewhere [20, 21]. In brief, Body mass index (BMI) was calculated using the formula 
[weight in kilograms (kg) divided by height squared (m2)]. Waist circumference (WC) was 
measured with an unstretched tape measure at the level of the umbilicus, without any pressure to 
the body surface. Hip circumference (HC) was measured at the level of the anterior superior iliac 
spine without any pressure to body surface. Systolic blood pressure (SBP) and diastolic blood 
pressure (DBP) were measured twice on the right arm in a seated position using a standard mercury 
sphygmomanometer after 15 mines of rest and the mean of these measurements was recorded. 
Blood samples were taken from participants after 12 h of overnight fasting and all blood analyses 
were performed at the TLGS research laboratory on the day of blood collection. Triglyceride (TG) 
levels were assayed using glycerol phosphate. Total cholesterol (TC) was assayed using the 
enzymatic colorimetric method with cholesterol esterase and cholesterol oxidase. Levels of high-
density lipoprotein cholesterol (HDL-C) were measured after precipitation of the apolipoprotein 
B (apo B)-containing lipoproteins with phosphotungstic acid; we used a modified Friedewald to 
calculate LDL-C. All metabolic analyses were performed using related kits (Pars Azmon Inc., 
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Tehran, Iran) and a Selecta 2 autoanalyzer (Vital Scientific, Spankeren, Netherlands). Intra-assay 
and inter-assay coefficients of variations for TG, TC, HDL-C, and LDL-C were less than 2.1, 1.9, 
3, and 3%, respectively. Serum creatinine (cr) levels were assayed by kinetic colorimetric Jaffe; 
sensitivity of the assay was 0.2 mg/dL (range, 18–1330 µmol/L (0.2–15 mg/dL). Reference 
intervals based on the manufacturer’s recommendation was 53–97 µmol/L (0.6–1.1 mg/dL) in 
men. Intra-assay and inter-assay CVs < 3.1% in both baseline and follow-up phases. All 
biochemical assays were performed using commercial kits (Pars Azmoon Inc., Tehran, Iran) using 
a Selectra 2 autoanalyzer (Vital Scientific, Spankeren, The Netherlands). Assay performance was 
monitored after every 25 tests using lyophilized serum controls in normal and pathologic ranges 
and all samples were analyzed only when the internal quality control met the standard acceptable 
criteria [20, 21]. 
Term definitions  
Data on history of PE were collected using a validated self-reporting questionnaire. According to 
the national guideline, the international standard criteria were used for the diagnosis of PE, i.e. the 
onset of a BP level ≥ 140/ 90 mm Hg along with proteinuria > 0.3 g/24 h after 20 weeks’ gestation 
(22).  
HTN was diagnosed based on the JNC-VI criteria (23), as a mean systolic blood pressure ≥ 140 
mm Hg, mean diastolic blood pressure ≥ 90 mm Hg, or the current use of anti-hypertensive 
medicine (24, 25).  
Chronic kidney disease (CKD) was defined as an estimated glomerular filtration rate <60 
mL/min/1.73m2 (26). In this study, GFR was estimated using the abbreviated prediction equation, 
provided by the Modification of Diet in Renal Disease (MDRD) study as follows: GFR = 186 × 
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(SCr) -1.154 × (Age) -0.203, in which eGFR (estimated GFR) is expressed as mL/min per 1.73 m2 
and serum creatinine (Scr) is expressed as mg/dL. Incident CKD was an eGFR of < 60 mL/min 
per 1.73 m2 occurring at any time during the follow-up period [20, 26, 27].  
Diabetes was defined as fasting plasma glucose (FPG) of ≥7.0 mmol/L or 2-hpost-challenge 
plasma glucose (2 h-PCPG) ≥11.1mmol/L or taking anti-diabetic medication in all phases of study 
Statistical analyses  
All continuous variables were assessed for normality using the one-sample Kolmogorov–Smirnoff 
test, and are expressed as mean (standard deviation), if variables had a normal distribution, or 
median with inter-quartile range (IQ25-75) for variables with skewed distribution. The 
characteristics of participants at baseline were compared between the PE and non-PE groups using 
two independent-sample t-tests or the equivalent nonparametric Mann-Whitney U test. Categorical 
variables, expressed as percentages, were compared using the Pearson’s test. To analyze the 
person-time incidence rate of CKD the following description was used: the number of new events 
of the condition (cases) in the study time divided by the sum of person-time (person * year) at risk 
in the study participants. Initially, all variables were included in the univariate model. Next, the 
variables found to be significant in the univariate model were further included in the multivariate 
model. Adjustment for diabetes and dyslipidemia did not have any effect on the magnitude of the 
estimates. Pooled logistic regression was used to assess (1) the association between the 
dichotomous outcome variable (PE) and time-dependent covariates as the data was interval 
censored and time to CKD was not known, and (2) to calculate odds ratios (OR). This model treats 
every interval as a mini follow-up study, pools the observations of all intervals together into one 
pooled sample and does a logistic regression on the pooled dataset. In addition, the multivariable 
analysis was repeated using the time-dependent Cox proportional hazard regression assuming the 
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CKD event occurs is in the mid-time between visits. Kaplan-Meier plots and log-rank tests were 
employed as the univariate test for between-group differences in survival from CKD. Cox’s 
proportional hazard model was used to calculate the hazard ratio between groups. Both these 
models were adjusted for age, BMI, SBP, DBP and smoking. Statistical analysis was performed 
using the software package STATA (version 14; STATA Inc., College station, TX, USA). 
Significance level was set at p < 0.05, with a confidence interval (CI) of 95%. 
Results 
Characteristics of the study subjects 
During 15 years of follow-up, 1851 eligible participants including 177 women with PE and 1674 
without PE were recruited; median and interquartile range for the follow-up years of PE and non-
PE groups were 7.78 (5.19-10.40) and 7.32 (4.73-11.00) years, respectively. Baseline 
characteristics of the subjects are presented in Table 1. 
Compared to non-PE controls, women with prior PE were more likely to be younger, [31.1 (7.4) 
versus 33.7 (7.5) years (P < 0.001)], and had significantly higher WC [86.5 (11.7) vs. 83.9 (10.7) 
cm, P = 0.002], BMI [(27.5 (4.6) vs. 26.5 (4.2) kg/m2, P = 0.003], WHR [(0.8 (0.07) vs. 0.8 (0.07), 
P < 0.02] as well as SBP (108.1 (9.4) mmHg vs. 105.3 (9.2) mmHg), and DBP (71.3 (5.8) mmHg 
vs. 69.6 (6.2) mmHg) levels. Moreover, there was no statistically significant difference in the 
proportion of current smoking between women with and without prior PE.  Based on the table 1 
the prevalence of DM was the same for both groups at baseline (p-value=0.2). Neither was the 
mean of FBS and BS significantly different in both groups at baseline. 
The total cumulative incidence rate of CKD at the median follow-up time was 35/100000 (95% 
CI: 25/100000, 50/100000) and 36/100000 (95% CI: 32/100000, 39/100000) in PE and non-PE 
women, respectively (P-value =0.90).  
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Pooled logistic regression and survival analysis 
According to the pooled logistic regression analysis, OR of CKD progression (adjusted for age, 
BMI, SBP and DBP) in the PE group was not significantly different compared to the non-PE one 
(OR: 1.04; P-value= 0.80; 95% CI: 0.77, 1.40) (Table 2). In addition, the interaction of age and 
PE status (not statistically significant) showed that the relationship between PE, and CKD 
progression, was not age dependent (table 2). 
The Kaplan-Meier plot, (Figure 2) illustrated the time for development of CKD for women in the 
PE and non-PE groups. The Kaplan-Meier plot for women with PE was not significantly different 
from that of non-PE women (P-value=0.35). Compared to non-PE women, women with prior PE 
did not have higher risk of developing CKD in the unadjusted model (unadjusted HR 1.1; 95% CI, 
0.83–1.69; P = 0.35), even after multiple adjustments for potential confounders related to CKD, 
including age, BMI and baseline SBP (multiple- adjusted HR 1.2; 95% CI, 0.84–1.7 P = 0.31) 
(Table 2). 
Pooled logistic and cox regression models for 4 subgroups of women including those with history 
of PE at: baseline (n=112), 1st follow up (n=43), 2nd follow up (n=22), and women without history 
of PE (n=1674) revealed no difference in incidence of CKD among these four sub-groups 
(supplementary table 1). 
Discussion 
This long-term, prospective and population-based study evaluated the incidence rate and risk of 
CKD among women with and without the prior history of PE. Without HTN, progression to CKD 
after the median follow-up time of 12 years was comparable between women with and without 
prior PE even after adjustment for potential confounders (age, BMI and blood pressure).  
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The underlying pathophysiology of preeclampsia is yet only partly understood. Impaired 
placentation at the early stage of gestations, as well as endothelial dysfunction, could play an 
important role in an affected pregnancy. It is well documented that kidney function alters during 
preeclamptic pregnancy; both renal blood flow and GFR decrease in preeclampsia, but absolute 
levels may remain above the non-pregnant range. It has been shown that renal lesions and 
glomerular deposits of various hemostatic factors can disappear within weeks after delivery [10]. 
In addition, data shows that decreased levels of GFR resolve a decade after preeclampsia that is 
comparable in women with and without a history of PE [9, 28]. However, microalbuminuria in 
women with prior PE is more likely to persist over the years, compared to controls of similar ages 
[28], which may be associated with developing of cardiovascular disease (CVD) and HTN in these 
women [29, 30]. Furthermore, CVD and HTN are comorbidities that may also accelerate the 
developing of subsequent CKD in these women. 
Results of studies focusing on CKD among women with the history of PE are controversial. In 
agreement with our findings, Paauw et al. (2018) in a well-designed long term longitudinal study 
with a median follow-up of 11 years, assessed kidney dysfunction including CKD and end-stage 
renal disease (ESRD) following the pregnancy hypertensive disorder; during follow-up, none of 
the women developed ESRD. In addition, hypertensive pregnancy disorder did not increase the 
incidence of CKD (HR, 1.04; 95% CI, 0.79-1.37; P=0.8) [13]. In another population-based study, 
Sandvik et al. (2013) using data from the Medical Birth Registry in Norway reported that 
preeclampsia was not associated with higher rates of microalbuminuria or increased urinary 
albumin excretion, i.e. Median urinary ACR: 0.53 mg/mmol and 0.50 mg/mmol for women with 
and without prior preeclampsia respectively, P=0.54 (31). In addition, a meta-analysis (2019) 
conducted on kidney disease after preeclampsia, of seven studies reported that 31 percent of 
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women with history of PE after a mean follow-up of 7 years, had microalbuminuria, which was 
much higher than the 7% observed in women without the condition. However, there was no 
significant difference in the GFR, estimated using urinary creatinine clearance (mean difference, -
0.04 mL/s [95% CI, -0.12 to 0.04] [9]. 
Other studies have focused mostly on end-stage renal disease. Vikse et al. (2008) demonstrated 
that prior preeclampsia could significantly increase the risk of end-stage renal disease 3-6 fold, 
depending on whether a woman had had pre-eclampsia in the first, second or both pregnancies 
[32]. A recent study by Kristensen et al (2019) evaluated associations between PE and later risk of 
kidney disease in a national register-based prospective study [18], in which more than one million 
women were followed for an average 18.6 years/woman; their results showed that compared with 
women without previous PE, those with a history of it were more likely to develop chronic renal 
conditions: HR 3.93, 95% CI: 2.90-5.33, for early preterm PE who delivered <34 weeks, 2.81 (2.1-
3.71) for late preterm PE who delivered 34-36 weeks and 2.27 (2.02-2.55) for term PE who 
delivered ≥37 weeks. However, the definition of CKD in this study differed to our study. They 
included hypertensive kidney disease, most glomerular disease diagnoses, chronic 
tubulointerstitial nephritis, and renal failure. Since maternal age and BMI are suspected of 
mediating the associations between PE and CKD, the effect of age and BMI in our model was 
adjusted, whereas they were not adjusted in that study.   
The main strengths of our study are its methodology as a long term prospective population-based 
study with a large sample size. Low levels of loss to follow-up are other strengths of this study, 
which helped us to estimate the study outcome with a high precision. However, our study was 
limited by a number of factors that should be considered when interpreting the results. 
Preeclampsia diagnosis was self-reported in this study, which may induce recall bias, affecting the 
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results; using the valid questionnaire that included proxy variables and checking the summary 
report of hospitalization for those with uncertain situation may reduce such bias (35, 36). In 
addition, it was reported that the self-reported history of hypertensive pregnancy disorders has a 
sensitivity of 72–80% and specificity of 96–99% (33, 34). Moreover, recurrent PE and severity of 
PE were not assessed, which might have influenced the severity of endothelial dysfunction after 
pregnancy. Furthermore, as in most epidemiologic studies, the CKD definition was based on 
creatinine measurements which may vary day-to-day (15.5–19.6%) and were not repeated within 
three months to confirm a chronic reduction in GFR. In addition, we lacked data on proteinuria or 
microalbuminuria (causing underestimation of CKD incidence) that could have given us more 
accurate results; however, eGFR as a measure of kidney function is closely linked to proteinuria 
(37, 38). Some epidemiologic studies use serum creatinine for definition of the CKD, a non-
expensive and simple method, easily applied for large population measurements (39). Also, despite 
controlling for various confounders in our analysis, residual confounding due to unknown or 
unmeasured confounders such as socioeconomic factors and family history of CKD cannot be 
excluded. Last but not least, since this study was performed only on Iranian women, the findings 
cannot be generalized to other population with different covariate distributions.  
Conclusion 
Women with the history of PE showed no higher risk of subsequent chronic kidney disease over 
15 years of follow up, a finding independent of the women’s age, BMI, SBP, and DBP. Further 
comprehensive prospective studies with a precise definition of the severity of PE and kidney 
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Table 1. Baseline characteristics of the women with and without history of preeclampsia 





Age a (years) 31.11 ( 7.45) 33.73 (7.54) < 0.001 
Parity a 0.97 (0.15) 1.00 (0.08) 0.14 
BMI a (kg/m2) 27.5 (4.60) 26.50 (4.23) 0.003 
WC a (cm) 86.58 (11.77) 83.91 ( 10.70) 0.002 
HC a (cm) 104.28 (9.24) 102.80 (8.35) 0.03 
Waist to hip ratio a 0.83 (0.07) 0.81 (0.07) 0.02 
SBP a (mmHg) 108.12 (9.46) 105.40 (9.21) < 0.001 
DBP a (mmHg) 71.34 (5.81) 69.60 (6.23) < 0.001 
TG b (mmol/L) 1.31 (0.87-1.88) 1.23 (0.88-1.81) 0.56 
TC a (mmol/L) 5.00 (1.07) 4.97 (1.04) 0.77 
LDL-C a (mmol/L) 3.20 (0.93) 3.13 (0.88) 0.40 
HDL-C a (mmol/L) 1.13 (0.28) 1.16 (0.29) 0.08 
Prevalence of DMc 8 (4.5) 50 (3) 0.2 
FBSa (mmol/L) 5±1.3 5±1.1 0.7 
2 h-PCPG a (mmol/L) 6±2.4 5.9±1.9 0.4 
Current Smoking c 10 (5.6%) 72 (4.3%) 0.44 
a values are presented as mean (SD). 
b presented as median (interquartile range). 
c data shown as number (percentage). 
d Significant differences (P-value<0.05), analyzed using independent t-test for superscripts a, 
Mann-Whitney U test for superscripts b , and Pearson’s 2  test for superscripts c. 
PE= preeclampsia; Non-PE= Non Preeclampsia; BMI= body mass index; WC= waist circumference; 
HC= hip circumference; SBP= systolic blood pressure; DBP= diastolic blood pressure; TG= 
triglycerides; TC= total cholesterol; LDL-C= Low-density lipoprotein cholesterol; HDL-C= high-
density lipoprotein cholesterol; HTN= hypertension; FPG= fasting plasma glucose; 2 h-PCPG=  2-

















Table 2. Pooled logistic regression and the cox regression model for CKD among women with 
and without preeclampsia. 
P-value 95% Confidence 
interval 
Odds Ratio Variables   





0.51 (0.14,2.62) 0.61 PE 
Multiple 
adjusted  
<0.001 (1.05, 1.08) 1.07 Age (year) 
0.47 (0.97, 1.05) 1.01 Age * PE 
0.80 (0.77, 1.40) 1.04 PE 
   Time 
  Reference Follow-up 1  
<0.001 (0.87, 1.43) 2.37 Follow-up 2  
<0.001 (1.13, 1.81) 2.82 Follow-up 3  
<0.001 (1.15, 1.96) 3.05 Follow-up 4  
<0.001 (1.05, 1.08) 1.07 Age (year) 
0.35 (0.97, 1.01) 0.99  BMI (kg/m2) 
0.39 (0.99, 1.01) 1.00  SBP (mmHg) 
0.68 (0.99, 1.02) 1.00 DBP (mmHg) 
0.12 (0.93, 1.93) 1.34 Smoking   
P-value 95% Confidence 
interval 
Hazard Ratio Variables   




0.45 (0.63, 1.23) 0.88 PE 
Multiple 
adjusted  
<0.001 (1.04, 1.07) 1.05 Age (year) 
0.67 (0.97, 1.01) 1.00 BMI (kg/m2) 
0.15 (0.97, 1.04) 1.02 SBP (mmHg) 
0.51 (0.98, 1.03) 1.01 DBP (mmHg) 
0.2 (0.89, 1.85) 1.28 Smoking   
























Figure 1. Study flowchart. 









Reproductive age women assessed for eligibility criteria  
(Aged 20-50 with at least one pregnancy) 
n= 3901 
History of PE 
n = 499 
No history of PE 
n = 3402 
Loss to follow up 
n = 26 
Loss to follow up 
n = 332 
Remained 
n = 1674 
Remained 
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Supplementary table 1: Pooled logistic and cox regression models for 4 subgroups of women 
including those with history of PE at: baseline (n=112), 1st follow up (n=43), 2nd follow up (n=22), 
and women without history of PE (n=1674) 
P-value 95% Confidence 
interval 












































   Time 
  Reference Follow-up 1  
<0.001 (1.75, 3.17) 2.36 Follow-up 2  
<0.001 (2.11, 3.75) 2.81 Follow-up 3  
<0.001 (2.27, 4.13) 3.07 Follow-up 4  
<0.001 (1.05, 1.08) 1.06 Age (year) 
0.35 (0.97, 1.01) 0.99  BMI (kg/m2) 
0.38 (0.99, 1.01) 1.00  SBP (mmHg) 
0.51 (0.99, 1.02) 1.00 DBP (mmHg) 
0.11 (0.93, 1.93) 1.35 Smoking   
P-value 95% Confidence 
interval 

































adjusted  <0.001 (1.04, 1.07) 1.05 Age (year) 
0.72 (0.97, 1.01) 1.00 BMI (kg/m2) 
0.49 (0.98, 1.01) 1.00 SBP (mmHg) 
0.64 (0.98, 1.01 1.00 DBP (mmHg) 
0.18 (0.89, 1.86) 1.29 Smoking   
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Background: Although preeclampsia (PE), as an endothelial disorder can lead to renal 
dysfunction during pregnancy, results of studies focusing on the potential long term potential 
effects of preeclampsia on renal function are insufficient and those available are controversial. 
This study investigated the incidence rate and risk of chronic kidney disease (CKD) among women 
with prior history of PE compared with healthy-controls in a long-term population-based study. 
Methods: This was a prospective population-based cohort study. Subjects were 1851 eligible 
women, aged 20–50 years, with at least one pregnancy (177 women with prior-PE and 1674 non-
PE controls) selected from among the Tehran-Lipid and Glucose-Study-participants. A pooled-
logistic-regression-model and Cox’s-proportional-hazards-models were utilized to estimate the 
risk of CKD in women of both PE and without PE groups, after further adjustment for confounders. 
Results: Median and interquartile ranges for follow-up durations of the PE and non-PE groups 
were 7.78 (5.19-10.40) and 7.32 (4.73-11.00) years, respectively. Total cumulative incidence rates 
of CKD at the median follow-up time of each group was 35/100000 (95% CI: 25/100000, 
50/100000) and 36/100000 (95% CI: 32/100000, 39/100000) in PE and non-PE women 
respectively. (P-value= 0.90). Based on pooled-logistic-regression-analysis, OR of CKD 
progression (adjusted for age, BMI, SBP and DBP) for the PE group did not differ, compared to 
their non-PE counterparts. (OR: 1.04; P-value= 0.80; 95% CI: 0.77, 1.40). Compared to non-PE 
women, women with prior PE did not have higher hazard ratios of developing CKD in the 
unadjusted model (unadjusted HR 1.1; 95% CI, 0.83–1.69; P = 0.35), results which remained 
unchanged after adjustment for age, BMI, baseline SBP and DBP.  
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Conclusion: Preeclampsia was not found to be a risk factor for CKD. More studies using a 
prospective cohort design with long term follow-ups are needed to investigate the relationship 
between preeclamsia and CKD. 
Keywords: preeclampsia, chronic kidney disease, prospective population- based study, Tehran-
Lipid and Glucose-Study (TLGS). 
Introduction 
Preeclampsia (PE) is a multisystem disorder affecting 3%–10% of all pregnant women with 
simultaneous increased rates of obesity, advanced maternal age and nulliparity [1, 2]. This disorder 
constitutes as a major cause of maternal morbidity and mortality worldwide.  
The exact underlying etiology and pathogenesis of PE remains unknown, although it has been 
shown that genetic, immunological and environmental factors are associated with the endothelial 
dysfunction of PE [3]. Moreover, the imbalance of proangiogenic and anti-angiogenic proteins and 
disturbances in the renin–angiotensin aldosterone system, common mechanisms in chronic kidney 
disease, may play an important role in PE [4, 5]. Endothelial dysfunction in PE can also affect 
kidney function; it is well documented that PE is strongly associated with acute kidney 
dysfunction, viz. glomerular endotheliosis [6]. Kidney dysfunction, reflected by either decreased 
glomerular filtration rate (GFR) or albuminuria that usually recovers within six weeks of birth [7], 
unless there is glomerular scarring [8]. Nonetheless, some women may experience persistently 
decreased kidney function long after their complicated pregnancy with PE [9].  
Relatively little is known about its long term effects on the kidney function later in life and data 
available reveal conflicting results. While some studies report kidney dysfunction can be resolved 
in most women with a history of PE [10-13], it has been shown that some women with PE may 
experience decreased glomerular filtration rate (GFR) and/or persistent proteinuria and/or 
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increased risk of CKD after PE [9, 14-18], discrepancies which may be partly explained by 
differences in ethnicities, study design, definition of kidney function and limited follow-up 
durations after pregnancy.  
Considering the data available on the history of PE of the Tehran-Lipid and Glucose-Study (TLGS) 
participants enabled us to compare the incidence of CKD events among women with a prior history 
of PE compared with healthy controls in a long-term population-based study. 
Methods 
The Medical Ethics Committee of the Research Institute for Endocrine Sciences approved the 
research protocol. Written informed consent was obtained from all participants before the initiation 
of the study. (Ethic code: IR.SBMU.ENDOCRINE.REC.1398074) 
Study population  
This was a prospective cohort study with a 15-year follow-up conducted among 1851 women aged 
20-50 years diagnosed with and without PE after the index pregnancy. The study participants were 
recruited from the Tehran Lipid and Glucose Study (TLGS). An ongoing study, initiated in 1998 
to investigate the prevalence and risk factors of non-communicable diseases, in particular, 
cardiovascular risk factors. Briefly, in the TLGS, a total of 15,005 individuals, aged ≥ 3 years, 
were followed within 3-years intervals to collect data on demographic, anthropometric, 
reproductive and metabolic characteristics, general physical examinations, and laboratory 
measurements. Details of the procedures of TLGS have been published previously [19]. All 
participants were visited at the outpatient clinic of TLGS between February 1999 and August 2001. 
At initiation of our study, TLGS completed five phases with 3-year intervals (phase 1: 1999-2001, 
phase 2: 2002-2005, phase 3: 2005- 2008, phase 4: 2008- 2011 and phase 5: 2011- 2014). 
Therefore, current data were available for five phases including baseline and four follow-ups.  
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At the beginning of this study, all women, aged 20-50 years with at least one pregnancy were 
assessed (n= 3901), of whom  499 women had a history of PE during their pregnancies and 3402 
did not. All women who were present at the baseline of the study and had at least one follow-up 
visit were included. Excluded were women with CKD (n= 203), hypertension (HTN) (n= 1265), 
CKD plus HTN (n= 224), and those without at least one follow up visit (n= 358). Finally, a total 
of 1851 women were recruited to participate in this study (Figure 1).  
Measurements   
All clinical, anthropometric, and biochemical parameters were measured by trained interviewers 
at baseline and follow-up visits; detailed descriptions of the measurements in TLGS have been 
published elsewhere [20, 21]. In brief, Body mass index (BMI) was calculated using the formula 
[weight in kilograms (kg) divided by height squared (m2)]. Waist circumference (WC) was 
measured with an unstretched tape measure at the level of the umbilicus, without any pressure to 
the body surface. Hip circumference (HC) was measured at the level of the anterior superior iliac 
spine without any pressure to body surface. Systolic blood pressure (SBP) and diastolic blood 
pressure (DBP) were measured twice on the right arm in a seated position using a standard mercury 
sphygmomanometer after 15 mines of rest and the mean of these measurements was recorded. 
Blood samples were taken from participants after 12 h of overnight fasting and all blood analyses 
were performed at the TLGS research laboratory on the day of blood collection. Triglyceride (TG) 
levels were assayed using glycerol phosphate. Total cholesterol (TC) was assayed using the 
enzymatic colorimetric method with cholesterol esterase and cholesterol oxidase. Levels of high-
density lipoprotein cholesterol (HDL-C) were measured after precipitation of the apolipoprotein 
B (apo B)-containing lipoproteins with phosphotungstic acid; we used a modified Friedewald to 
calculate LDL-C. All metabolic analyses were performed using related kits (Pars Azmon Inc., 
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Tehran, Iran) and a Selecta 2 autoanalyzer (Vital Scientific, Spankeren, Netherlands). Intra-assay 
and inter-assay coefficients of variations for TG, TC, HDL-C, and LDL-C were less than 2.1, 1.9, 
3, and 3%, respectively. Serum creatinine (cr) levels were assayed by kinetic colorimetric Jaffe; 
sensitivity of the assay was 0.2 mg/dL (range, 18–1330 µmol/L (0.2–15 mg/dL). Reference 
intervals based on the manufacturer’s recommendation was 53–97 µmol/L (0.6–1.1 mg/dL) in 
men. Intra-assay and inter-assay CVs < 3.1% in both baseline and follow-up phases. All 
biochemical assays were performed using commercial kits (Pars Azmoon Inc., Tehran, Iran) using 
a Selectra 2 autoanalyzer (Vital Scientific, Spankeren, The Netherlands). Assay performance was 
monitored after every 25 tests using lyophilized serum controls in normal and pathologic ranges 
and all samples were analyzed only when the internal quality control met the standard acceptable 
criteria [20, 21]. 
Term definitions  
Data on history of PE were collected using a validated self-reporting questionnaire. According to 
the national guideline, the international standard criteria were used for the diagnosis of PE, i.e. the 
onset of a BP level ≥ 140/ 90 mm Hg along with proteinuria > 0.3 g/24 h after 20 weeks’ gestation 
(22).  
HTN was diagnosed based on the JNC-VI criteria (23), as a mean systolic blood pressure ≥ 140 
mm Hg, mean diastolic blood pressure ≥ 90 mm Hg, or the current use of anti-hypertensive 
medicine (24, 25).  
Chronic kidney disease (CKD) was defined as an estimated glomerular filtration rate <60 
mL/min/1.73m2 (26). In this study, GFR was estimated using the abbreviated prediction equation, 
provided by the Modification of Diet in Renal Disease (MDRD) study as follows: GFR = 186 × 
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(SCr) -1.154 × (Age) -0.203, in which eGFR (estimated GFR) is expressed as mL/min per 1.73 m2 
and serum creatinine (Scr) is expressed as mg/dL. Incident CKD was an eGFR of < 60 mL/min 
per 1.73 m2 occurring at any time during the follow-up period [20, 26, 27].  
Diabetes was defined as fasting plasma glucose (FPG) of ≥7.0 mmol/L or 2-hpost-challenge 
plasma glucose (2 h-PCPG) ≥11.1mmol/L or taking anti-diabetic medication in all phases of study 
Statistical analyses  
All continuous variables were assessed for normality using the one-sample Kolmogorov–Smirnoff 
test, and are expressed as mean (standard deviation), if variables had a normal distribution, or 
median with inter-quartile range (IQ25-75) for variables with skewed distribution. The 
characteristics of participants at baseline were compared between the PE and non-PE groups using 
two independent-sample t-tests or the equivalent nonparametric Mann-Whitney U test. Categorical 
variables, expressed as percentages, were compared using the Pearson’s test. To analyze the 
person-time incidence rate of CKD the following description was used: the number of new events 
of the condition (cases) in the study time divided by the sum of person-time (person * year) at risk 
in the study participants. Initially, all variables were included in the univariate model. Next, the 
variables found to be significant in the univariate model were further included in the multivariate 
model. Adjustment for diabetes and dyslipidemia did not have any effect on the magnitude of the 
estimates. Pooled logistic regression was used to assess (1) the association between the 
dichotomous outcome variable (PE) and time-dependent covariates as the data was interval 
censored and time to CKD was not known, and (2) to calculate odds ratios (OR). This model treats 
every interval as a mini follow-up study, pools the observations of all intervals together into one 
pooled sample and does a logistic regression on the pooled dataset. In addition, the multivariable 
analysis was repeated using the time-dependent Cox proportional hazard regression assuming the 
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CKD event occurs is in the mid-time between visits. Kaplan-Meier plots and log-rank tests were 
employed as the univariate test for between-group differences in survival from CKD. Cox’s 
proportional hazard model was used to calculate the hazard ratio between groups. Both these 
models were adjusted for age, BMI, SBP, DBP and smoking. Statistical analysis was performed 
using the software package STATA (version 14; STATA Inc., College station, TX, USA). 
Significance level was set at p < 0.05, with a confidence interval (CI) of 95%. 
Results 
Characteristics of the study subjects 
During 15 years of follow-up, 1851 eligible participants including 177 women with PE and 1674 
without PE were recruited; median and interquartile range for the follow-up years of PE and non-
PE groups were 7.78 (5.19-10.40) and 7.32 (4.73-11.00) years, respectively. Baseline 
characteristics of the subjects are presented in Table 1. 
Compared to non-PE controls, women with prior PE were more likely to be younger, [31.1 (7.4) 
versus 33.7 (7.5) years (P < 0.001)], and had significantly higher WC [86.5 (11.7) vs. 83.9 (10.7) 
cm, P = 0.002], BMI [(27.5 (4.6) vs. 26.5 (4.2) kg/m2, P = 0.003], WHR [(0.8 (0.07) vs. 0.8 (0.07), 
P < 0.02] as well as SBP (108.1 (9.4) mmHg vs. 105.3 (9.2) mmHg), and DBP (71.3 (5.8) mmHg 
vs. 69.6 (6.2) mmHg) levels. Moreover, there was no statistically significant difference in the 
proportion of current smoking between women with and without prior PE.  Based on the table 1 
the prevalence of DM was the same for both groups at baseline (p-value=0.2). Neither was the 
mean of FBS and BS significantly different in both groups at baseline. 
The total cumulative incidence rate of CKD at the median follow-up time was 35/100000 (95% 
CI: 25/100000, 50/100000) and 36/100000 (95% CI: 32/100000, 39/100000) in PE and non-PE 
women, respectively (P-value =0.90).  
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Pooled logistic regression and survival analysis 
According to the pooled logistic regression analysis, OR of CKD progression (adjusted for age, 
BMI, SBP and DBP) in the PE group was not significantly different compared to the non-PE one 
(OR: 1.04; P-value= 0.80; 95% CI: 0.77, 1.40) (Table 2). In addition, the interaction of age and 
PE status (not statistically significant) showed that the relationship between PE, and CKD 
progression, was not age dependent (table 2). 
The Kaplan-Meier plot, (Figure 2) illustrated the time for development of CKD for women in the 
PE and non-PE groups. The Kaplan-Meier plot for women with PE was not significantly different 
from that of non-PE women (P-value=0.35). Compared to non-PE women, women with prior PE 
did not have higher risk of developing CKD in the unadjusted model (unadjusted HR 1.1; 95% CI, 
0.83–1.69; P = 0.35), even after multiple adjustments for potential confounders related to CKD, 
including age, BMI and baseline SBP (multiple- adjusted HR 1.2; 95% CI, 0.84–1.7 P = 0.31) 
(Table 2). 
Pooled logistic and cox regression models for 4 subgroups of women including those with history 
of PE at: baseline (n=112), 1st follow up (n=43), 2nd follow up (n=22), and women without history 
of PE (n=1674) revealed no difference in incidence of CKD among these four sub-groups 
(supplementary table 1). 
Discussion 
This long-term, prospective and population-based study evaluated the incidence rate and risk of 
CKD among women with and without the prior history of PE. Without HTN, progression to CKD 
after the median follow-up time of 12 years was comparable between women with and without 
prior PE even after adjustment for potential confounders (age, BMI and blood pressure).  
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The underlying pathophysiology of preeclampsia is yet only partly understood. Impaired 
placentation at the early stage of gestations, as well as endothelial dysfunction, could play an 
important role in an affected pregnancy. It is well documented that kidney function alters during 
preeclamptic pregnancy; both renal blood flow and GFR decrease in preeclampsia, but absolute 
levels may remain above the non-pregnant range. It has been shown that renal lesions and 
glomerular deposits of various hemostatic factors can disappear within weeks after delivery [10]. 
In addition, data shows that decreased levels of GFR resolve a decade after preeclampsia that is 
comparable in women with and without a history of PE [9, 28]. However, microalbuminuria in 
women with prior PE is more likely to persist over the years, compared to controls of similar ages 
[28], which may be associated with developing of cardiovascular disease (CVD) and HTN in these 
women [29, 30]. Furthermore, CVD and HTN are comorbidities that may also accelerate the 
developing of subsequent CKD in these women. 
Results of studies focusing on CKD among women with the history of PE are controversial. In 
agreement with our findings, Paauw et al. (2018) in a well-designed long term longitudinal study 
with a median follow-up of 11 years, assessed kidney dysfunction including CKD and end-stage 
renal disease (ESRD) following the pregnancy hypertensive disorder; during follow-up, none of 
the women developed ESRD. In addition, hypertensive pregnancy disorder did not increase the 
incidence of CKD (HR, 1.04; 95% CI, 0.79-1.37; P=0.8) [13]. In another population-based study, 
Sandvik et al. (2013) using data from the Medical Birth Registry in Norway reported that 
preeclampsia was not associated with higher rates of microalbuminuria or increased urinary 
albumin excretion, i.e. Median urinary ACR: 0.53 mg/mmol and 0.50 mg/mmol for women with 
and without prior preeclampsia respectively, P=0.54 (31). In addition, a meta-analysis (2019) 
conducted on kidney disease after preeclampsia, of seven studies reported that 31 percent of 
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women with history of PE after a mean follow-up of 7 years, had microalbuminuria, which was 
much higher than the 7% observed in women without the condition. However, there was no 
significant difference in the GFR, estimated using urinary creatinine clearance (mean difference, -
0.04 mL/s [95% CI, -0.12 to 0.04] [9]. 
Other studies have focused mostly on end-stage renal disease. Vikse et al. (2008) demonstrated 
that prior preeclampsia could significantly increase the risk of end-stage renal disease 3-6 fold, 
depending on whether a woman had had pre-eclampsia in the first, second or both pregnancies 
[32]. A recent study by Kristensen et al (2019) evaluated associations between PE and later risk of 
kidney disease in a national register-based prospective study [18], in which more than one million 
women were followed for an average 18.6 years/woman; their results showed that compared with 
women without previous PE, those with a history of it were more likely to develop chronic renal 
conditions: HR 3.93, 95% CI: 2.90-5.33, for early preterm PE who delivered <34 weeks, 2.81 (2.1-
3.71) for late preterm PE who delivered 34-36 weeks and 2.27 (2.02-2.55) for term PE who 
delivered ≥37 weeks. However, the definition of CKD in this study differed to our study. They 
included hypertensive kidney disease, most glomerular disease diagnoses, chronic 
tubulointerstitial nephritis, and renal failure. Since maternal age and BMI are suspected of 
mediating the associations between PE and CKD, the effect of age and BMI in our model was 
adjusted, whereas they were not adjusted in that study.   
The main strengths of our study are its methodology as a long term prospective population-based 
study with a large sample size. Low levels of loss to follow-up are other strengths of this study, 
which helped us to estimate the study outcome with a high precision. However, our study was 
limited by a number of factors that should be considered when interpreting the results. 
Preeclampsia diagnosis was self-reported in this study, which may induce recall bias, affecting the 
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results; using the valid questionnaire that included proxy variables and checking the summary 
report of hospitalization for those with uncertain situation may reduce such bias (35, 36). In 
addition, it was reported that the self-reported history of hypertensive pregnancy disorders has a 
sensitivity of 72–80% and specificity of 96–99% (33, 34). Moreover, recurrent PE and severity of 
PE were not assessed, which might have influenced the severity of endothelial dysfunction after 
pregnancy. Furthermore, as in most epidemiologic studies, the CKD definition was based on 
creatinine measurements which may vary day-to-day (15.5–19.6%) and were not repeated within 
three months to confirm a chronic reduction in GFR. In addition, we lacked data on proteinuria or 
microalbuminuria (causing underestimation of CKD incidence) that could have given us more 
accurate results; however, eGFR as a measure of kidney function is closely linked to proteinuria 
(37, 38). Some epidemiologic studies use serum creatinine for definition of the CKD, a non-
expensive and simple method, easily applied for large population measurements (39). Also, despite 
controlling for various confounders in our analysis, residual confounding due to unknown or 
unmeasured confounders such as socioeconomic factors and family history of CKD cannot be 
excluded. Last but not least, since this study was performed only on Iranian women, the findings 
cannot be generalized to other population with different covariate distributions.  
Conclusion 
Women with the history of PE showed no higher risk of subsequent chronic kidney disease over 
15 years of follow up, a finding independent of the women’s age, BMI, SBP, and DBP. Further 
comprehensive prospective studies with a precise definition of the severity of PE and kidney 
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